Recent Finacing
Recent Raise
Bolt Biotherapeutics develops Boltbody Immune‑Stimulating Antibody Conjugates (ISACs) that conjugate tumor-targeting antibodies with TLR7/8 agonists for systemic administration to reprogram the tumor microenvironment; lead program BDC-1001 targets HER2.
